142 related articles for article (PubMed ID: 23148638)
41. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
Harshman LC; Barbeau S; McMillian A; Srinivas S
Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238
[TBL] [Abstract][Full Text] [Related]
42. Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.
Santoni M; De Tursi M; Felici A; Lo Re G; Ricotta R; Ruggeri EM; Sabbatini R; Santini D; Vaccaro V; Milella M
Expert Rev Anticancer Ther; 2013 Jun; 13(6):697-709. PubMed ID: 23773104
[TBL] [Abstract][Full Text] [Related]
43. Emerging tyrosine kinase inhibitors for the treatment of renal cancer.
Iacovelli R; Albiges L; Escudier B
Expert Opin Emerg Drugs; 2015 Sep; 20(3):379-92. PubMed ID: 25982181
[TBL] [Abstract][Full Text] [Related]
44. Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma.
Romero-Laorden N; Doger B; Hernandez M; Hernandez C; Rodriguez-Moreno JF; Garcia-Donas J
Clin Transl Oncol; 2016 Jan; 18(1):1-8. PubMed ID: 26169213
[TBL] [Abstract][Full Text] [Related]
45. Molecular basis for the treatment of renal cell carcinoma.
Suárez C; Morales R; Muñoz E; Rodón J; Valverde CM; Carles J
Clin Transl Oncol; 2010 Jan; 12(1):15-21. PubMed ID: 20080466
[TBL] [Abstract][Full Text] [Related]
46. Update on the epidemiology and biology of renal cortical neoplasms.
Collins S; McKiernan J; Landman J
J Endourol; 2006 Dec; 20(12):975-85. PubMed ID: 17206887
[TBL] [Abstract][Full Text] [Related]
47. Anti-Angiogenic Drugs in the Treatment of Metastatic Renal Cell Carcinoma: Advances in Clinical Application.
Nielsen OH; Grimm D; Wehland M; Bauer J; Magnusson NE
Curr Vasc Pharmacol; 2015; 13(3):381-91. PubMed ID: 24548189
[TBL] [Abstract][Full Text] [Related]
48. Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization.
Garcia-Donas J; Rodriguez-Moreno JF; Romero-Laorden N; Rodriguez-Antona C
Urol Oncol; 2015 Apr; 33(4):179-86. PubMed ID: 24495452
[TBL] [Abstract][Full Text] [Related]
49. The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review.
Poletto V; Rosti V; Biggiogera M; Guerra G; Moccia F; Porta C
Crit Rev Oncol Hematol; 2018 Dec; 132():89-99. PubMed ID: 30447930
[TBL] [Abstract][Full Text] [Related]
50. Current management and future perspectives of metastatic renal cell carcinoma.
Lee-Ying R; Lester R; Heng D
Int J Urol; 2014 Sep; 21(9):847-55. PubMed ID: 24862210
[TBL] [Abstract][Full Text] [Related]
51. Combination therapy for renal cell cancer: what are possible options?
Santos N; Wenger JB; Havre P; Liu Y; Dagan R; Imanirad I; Ivey AM; Zlotecki RA; Algood CB; Gilbert SM; Allegra CJ; Okunieff P; Vieweg J; Dang NH; Luesch H; Dang LH
Oncology; 2011; 81(3-4):220-9. PubMed ID: 22085914
[TBL] [Abstract][Full Text] [Related]
52. Everolimus resistance in clear cell renal cell carcinoma: miRNA-101 and HIF-2α as molecular triggers?
Nogueira I; Dias F; Morais M; Teixeira AL; Medeiros R
Future Oncol; 2019 Jul; 15(20):2361-2370. PubMed ID: 31267758
[No Abstract] [Full Text] [Related]
53. Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.
Yamamoto K; Yano I
Med Oncol; 2018 Jan; 35(2):16. PubMed ID: 29302760
[TBL] [Abstract][Full Text] [Related]
54. The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions.
Choueiri TK; Motzer RJ
J Natl Compr Canc Netw; 2015 Oct; 13(10):1168-70. PubMed ID: 26483056
[No Abstract] [Full Text] [Related]
55. Pediatric Patient With Renal Cell Carcinoma Treated by Successive Antiangiogenics Drugs: A Case Report and Review of the Literature.
Jiménez I; Brisse HJ; Fréneaux P; Sarnacki S; Michon J; Orbach D; Pierron G; Clément N; Doz F; Escudier B; Schleiermacher G
J Pediatr Hematol Oncol; 2017 Jul; 39(5):e279-e284. PubMed ID: 28338568
[TBL] [Abstract][Full Text] [Related]
56. Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results.
Comandone A; Vana F; Comandone T; Tucci M
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885006
[TBL] [Abstract][Full Text] [Related]
57. Targeted therapy for renal cell carcinoma: a new treatment paradigm.
Hutson TE
Proc (Bayl Univ Med Cent); 2007 Jul; 20(3):244-8. PubMed ID: 17637878
[TBL] [Abstract][Full Text] [Related]
58. Renal effects of targeted anticancer therapies.
Porta C; Cosmai L; Gallieni M; Pedrazzoli P; Malberti F
Nat Rev Nephrol; 2015 Jun; 11(6):354-70. PubMed ID: 25734768
[TBL] [Abstract][Full Text] [Related]
59. mTOR Pathway Mutations and Response to Rapalogs in RCC-Letter.
Roldan-Romero JM; Rodríguez-Moreno JF; García-Donás J; Rodríguez-Antona C
Clin Cancer Res; 2017 Sep; 23(17):5320. PubMed ID: 28864728
[No Abstract] [Full Text] [Related]
60. [Management of side effects of targeted therapies in renal cancer: cutaneous side effects].
Robert C; Gimel P
Bull Cancer; 2011; 98(3 Suppl):S35-46. PubMed ID: 25819125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
